FG Cardio Completo
Pharmacogenetics in Cardiology
Why undergoing this exam?
Cardiovascular diseases encompass a set of pathologies related to the heart and blood vessels, which can occur due to genetic as well as environmental factors. Among the related cardiovascular and metabolic diseases, notable ones include hyperlipidemia, arterial hypertension, diabetes mellitus, coagulation disorders, and arrhythmias.
The pharmacological treatment of cardiovascular diseases is based on the use of various medications aimed at alleviating both the causes and symptoms of the disease.
Even with recent advances in pharmacological treatment, not all patients with cardiovascular diseases respond adequately to medication. Human genome variation is one of the most important factors responsible for modulating the individual response to pharmacological treatment.
What is this exam?
The FG Cardio Completo pharmacogenetic panel evaluates the main metabolizing enzymes and targets involved in the effect and toxicity of different drugs used in the treatment of cardiovascular diseases, providing the ability to select the most suitable drug and individually guide the dose for each patient.
For whom is it indicated?
- Patients with cardiovascular diseases who want to personalize treatment based on their genetic profile;
- Patients with cardiovascular diseases for whom pharmacological treatment does not yield expected results.
Technology
Next-generation sequencing (NGS).
FG Cardio Completo
Pharmacogenetics in Cardiology
Cardiovascular diseases encompass a set of pathologies related to the heart and blood vessels, which can occur due to genetic as well as environmental factors. Among the related cardiovascular and metabolic diseases, notable ones include hyperlipidemia, arterial hypertension, diabetes mellitus, coagulation disorders, and arrhythmias.
The pharmacological treatment of cardiovascular diseases is based on the use of various medications aimed at alleviating both the causes and symptoms of the disease.
Even with recent advances in pharmacological treatment, not all patients with cardiovascular diseases respond adequately to medication. Human genome variation is one of the most important factors responsible for modulating the individual response to pharmacological treatment.
The FG Cardio Completo pharmacogenetic panel evaluates the main metabolizing enzymes and targets involved in the effect and toxicity of different drugs used in the treatment of cardiovascular diseases, providing the ability to select the most suitable drug and individually guide the dose for each patient.
- Patients with cardiovascular diseases who want to personalize treatment based on their genetic profile;
- Patients with cardiovascular diseases for whom pharmacological treatment does not yield expected results.
Next-generation sequencing (NGS).
Advantages
SYNLAB GROUP
Guaranteed by the experience of the absolute European leader in laboratory diagnostics.
COMPLETE
Detailed report, including the type of metabolism of each enzyme, which drugs may cause toxic effects and adverse reactions, as well as recommendations on doses.
Additional Information
DOCUMENTATION – Available on the SYNLAB Direct for clients
- Informed Consent;
- Clinical Questionnaire;
- Medical Request.
PREPARATION
- Fasting is not necessary for the test.
Delivery Time
22 business days
Sample Type
5mL of total blood in EDTA
Other exams pharmacogenetics:
NEURO PGx
Genetic Analysis of Drug Response
GLOBAL PGx
Genetic Analysis of Drug Response
FG Onco Lapatinib
Pharmacogenetics of lapatinib treatment
FG Neuro Epilepsy
Pharmacogenetics of Epilepsies
FG Cardio Completo
Pharmacogenetics in Cardiology